---
title: "Nomura Raises PHARMARON  TP to HKD32.2 on Higher FY Revenue Forecast Driven by Order Backlog"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293892873.md"
description: "Nomura raised PHARMARON'starget price to HKD32.2 from HKD27.33, maintaining a Buy rating. This adjustment follows an increased FY2026 revenue forecast driven by strong order backlog and expected Q2 revenue growth of 19.4% YoY. While the earnings forecast was lowered by 7.6% due to negative foreign exchange impacts, gross margins are projected to rise to 35.1%. Nomura anticipates robust H2 performance with net profit expected to grow 27% YoY."
datetime: "2026-07-27T07:12:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293892873.md)
  - [en](https://longbridge.com/en/news/293892873.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293892873.md)
generator: "portal-rs"
---

# Nomura Raises PHARMARON  TP to HKD32.2 on Higher FY Revenue Forecast Driven by Order Backlog

Nomura published a research report forecasting that PHARMARON (03759.HK) +0.060 (+0.254%) Short selling $2.80M; Ratio 4.374% 's 2Q26 revenue will grow 19.4% YoY to about RMB4 billion. Among them, laboratory services and chemistry, manufacturing and controls services are expected to increase 20% and 25% YoY respectively. Driven by a higher contribution from high-margin laboratory services, gross margin is expected to rise to 35.1%, while net profit is estimated to grow 9.3% YoY to RMB433 million.

On expectations of strong 1H26 results and a solid order backlog, which is expected to grow more than 30% YoY, Nomura raised its FY2026 revenue forecast for PHARMARON by 2%, while lowering its earnings forecast by 7.6% to reflect negative foreign exchange impacts. Nomura currently forecasts the company's 2H26 revenue to grow 16.6% YoY to RMB8.9 billion, with net profit expected to increase 27% YoY to RMB1.2 billion. It maintained a Buy rating and raised the TP from HKD27.33 to HKD32.2.(gc/j)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-27 12:25.)

### Related Stocks

- [03759.HK](https://longbridge.com/en/quote/03759.HK.md)
- [300759.CN](https://longbridge.com/en/quote/300759.CN.md)
- [8604.JP](https://longbridge.com/en/quote/8604.JP.md)
- [NMR.US](https://longbridge.com/en/quote/NMR.US.md)

## Related News & Research

- [CICC Raises PHARMARON  TP to HKD28; Strong New Orders Support Solid Growth](https://longbridge.com/en/news/284690244.md)
- [Pharmaron Restructures H Share Awards Amid FX Policy Changes](https://longbridge.com/en/news/291548386.md)
- [FX hedging activity among North American funds at four-year high, survey shows](https://longbridge.com/en/news/296182400.md)
- [BOC AVIATION  Interim Net Profit Rises 4% YoY to USD357 million; Interim DPS USD17.99 Cents](https://longbridge.com/en/news/296463833.md)
- [Hanwha Investment & Securities Adds New FX-Linked Bond to Derivatives Shelf](https://longbridge.com/en/news/296435881.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**